Navigation Links
Alzheimer's cognitive decline slowed

PET scans and cognitive tests have suggested that Alzheimer's disease patients with genetically modified tissue inserted directly into their brains show a reduction in the rate of cognitive decline and increased metabolic activity in the brain, according to a study published in the April 24, 2005 online issue of the journal Nature Medicine by researchers at the University of California, San Diego (UCSD) School of Medicine.

PET scans demonstrated an increase in the brain's use of glucose, an indication of increased brain activity, while mental-status tests showed a slowing of the patients' rate of cognitive decline was reduced by 36 to 51 percent. In addition, researchers examined the brain tissue of a study participant who had died and found robust growth of extensions from the dying cholinergic cells near the site of growth factor gene delivery. Cholinergic neuron loss is a cardinal feature of Alzheimer's disease, a progressive brain disorder affecting memory, learning, attention and other cognitive processes.

"If validated in further clinical trials, this would represent a substantially more effective therapy than current treatments for Alzheimer's disease," said Mark Tuszynski, M.D., Ph.D., UCSD professor of neurosciences, neurologist with the VA San Diego Healthcare System, and the study's principal investigator. "This would also represent the first therapy for a human neurological disease that acts by preventing cell death."

In this first-ever gene therapy for Alzheimer's disease, UCSD physician-scientists took skin cells from eight patients diagnosed with early Alzheimer's disease. The tissue was modified in the lab to express nerve growth factor (NGF), a naturally occurring protein that prevents cell death and stimulates cell function. In surgeries that took place in 2001 and 2002 at UCSD's John M. and Sally B. Thornton Hospital, the genetically modified tissue was implanted deep within the brains of the eight patients who had volunteer ed for the study.

The human clinical trial was undertaken following extensive studies in primates conducted by Tuszynski and colleagues, which showed that grafting NGF-producing tissue into the brains of aged monkeys restored atrophied brain cells to near-normal size and quantity, and also restored axons connecting the brain cells, essential for communication between cells. The recent human studies were a Phase I clinical trial, designed to test safety and toxicity. The procedure was initially performed while patients were awake but lightly sedated, and two patients moved as the cells were being injected, resulting in bleeding in the brain. One of these patients died five week later. As a result of the bleeds, the protocol was redesigned to perform the procedure under general anesthesia and all subsequent procedures were performed without complication.

Cognitive outcomes were assessed in the six patients who completed the NGF delivery procedure safely. The Mini Mental Status Examination (MMSE), which evaluates cognitive function, was administered at screening, the time of treatment and at several intervals after treatment. Over an average post-treatment follow-up period of 22 months, the rate of decline on the MMSE among NGF-treated patients was reduced by as much as 51 percent. An additional test, called the Alzheimer's Disease Assessment Scale-Cognitive Subcomponent, or ADAS-Cog, also showed improvements in rates of decline followed the MMSE findings.

Post-operative PET scans in four subjects showed significant increases in the brain's absorption of a radioisotope called 18-fluorodeoxyglucose, an indicator of increased metabolic activity in the brain. The researchers noted that the increase was observed in most cortical regions that receive cholinergic input from forebrain nerve cells called the nucleus basalis, and in the cerebellum, a structure associated with cortical plasticity.

In addition to Tuszynski, authors of the paper in Nature Medicine, were Leon Thal, M.D., UCSD chair of neurosciences, director of the UCSD Shiley-Marcos Alzheimer's Disease Research Center (ADRC), and a neurologist with the VA San Diego Healthcare System; Mary Margaret Pay., R.N., David P. Salmon, Ph.D., Armin Blesch, Ph.D., Gilbert Ho, M.D., Gang Tong, M.D., Lawrence Hansen, M.D., and James Conner, Ph.D., of the UCSD Department of Neurosciences; Hoi Sang U, M.D., UCSD Department of Surgery; Lee Vahlsing, M.S., UCSD Department of Neurosciences and VA San Diego Healthcare System; Roy Bakay, M.D., Rush University Department of Surgery; Piyush Patel, M.D., UCSD Department of Anesthesiology; Steven G. Potkin, M.D. and Christine Gall, Ph.D., UC Irvine Department of Neurology; James Fallon, Ph.D., UC Irvine Department of Neurobiology; Elliott J. Mufson, Ph.D. and Jeffrey H. Kordower, Ph.D., Rush University Department of Neurosciences.


'"/>

Source:University of California - San Diego


Related biology news :

1. Neuronal traffic jam marks early Alzheimers disease
2. Mouse brain cells rapidly recover after Alzheimers plaques are cleared
3. Gene vaccine for Alzheimers disease shows promising results
4. Duke Chemists Isolating Individual Molecules Of Toxic Protein In Alzheimers, Parkinsons Disease
5. Nanoscale Diagnostic Sets Sights on Alzheimers
6. One gene links newborn neurons with those that die in diseases such as Alzheimers
7. Scientists discover that three molecules may be developed into new Alzheimers drugs
8. Pinpointing a culprit molecule in Alzheimers disease
9. Targeting a key enzyme with gene therapy reversed course of Alzheimers disease in mouse models
10. Hope for Alzheimers blossoms
11. Natural compound from pond scum shows potential activity against Alzheimers
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/16/2017)... 2017 - Against identity fraud with DERMALOG solutions "Made in Germany "  ... ... project, multi-biometric solutions provide a crucial contribution against identity fraud. (PRNewsFoto/Dermalog Identification Systems) ... Used combined in one project, multi-biometric solutions provide a crucial contribution against ... ...
(Date:3/7/2017)... March 7, 2017 Brandwatch , the leading social ... The Prince,s Trust to uncover insights to support its reporting, ... The UK,s leading youth charity will be using Brandwatch ... and get a better understanding of the topics and issues that ... ...
(Date:3/2/2017)... 2017 Summary This report provides ... KGaA and its partnering interests and activities since 2010. ... Description The Partnering Deals and Alliance since 2010 report ... one of the world,s leading life sciences companies. ... to ensure inclusion of the most up to date ...
Breaking Biology News(10 mins):
(Date:3/24/2017)... Sinovac Biotech Ltd. ("Sinovac" or the "Company") (NASDAQ: SVA), ... , today announced that its board of directors has amended its ... from March 27, 2017 to March 27, 2018. The amendment was not ... Biotech Ltd. ... Sinovac Biotech Ltd. is a China -based ...
(Date:3/24/2017)... -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with ... today announced participation at the following conferences: ... Maidstone Life Sciences conference "Cancer Immunotherapy Conference" at the ... York, NY . Agenus will participate in three ... Robert B. Stein , M.D., Ph.D., President, R&D ...
(Date:3/23/2017)... Research and Markets has announced the addition of the ... ... The Global Market for Bioproducts Should Reach $714.6 Billion by ... 8.9%, This research report quantifies the two ... segments: bio-derived chemicals, biofuels, pharmaceuticals (biodrugs and herbal/botanicals), biocomposite materials, ...
(Date:3/23/2017)... LOUISVILLE, Colo. , March 23, 2017  GlobeImmune, ... purchase agreement for the sale of 12,835,490 shares of ... the  NantWorks  ecosystem of companies. In connection with the sale ... GlobeImmune $100,000 in cash and issue to GlobeImmune 200,000 ... common stock. "We are pleased to ...
Breaking Biology Technology: